Literature DB >> 12594906

Modern surgical antibiotic prophylaxis and therapy--less is more.

P S Barie1.   

Abstract

Recent findings and recommendations on the use of antibiotics in surgery, both prophylactically and as therapy, suggest that adverse events associated with antibiotics remain a major cause of morbidity and mortality. Wound infection rates generally parallel the presence of one or more of three key risk factors; the overall medical condition of the patient, a prolonged operative time, and a contaminated or dirty operative field. The first choice of prophylactic drug should generally be a first- or second-generation cephalosporin, unless the patient is highly allergic to penicillin. Effective prophylaxis can almost always be achieved with a single dose of antibiotic, but the dose must be administered soon before the incision. New guidelines for the prevention of bacterial endocarditis have reduced both the types of cases that require prophylaxis, and the doses of antibiotic necessary to achieve prophylaxis. Some cases that required endocarditis prophylaxis previously no longer require prophylaxis. Rational antibiotic therapy demands rapid diagnosis and treatment. It is also crucial to distinguish among infection, contamination, and inflammation as soon as possible; contamination requires only a single dose of antibiotic, whereas sterile inflammation requires none at all. The choice of antibiotic for postoperative infection, including intra-abdominal infection, should consider the severity of illness and the risk of resistant bacteria. Failure to stratify for risk may prolong treatment unnecessarily, confound the interpretation of future studies, and increase the prevalence of bacterial resistance.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 12594906     DOI: 10.1089/109629600321263

Source DB:  PubMed          Journal:  Surg Infect (Larchmt)        ISSN: 1096-2964            Impact factor:   2.150


  12 in total

Review 1.  Meta-analysis of the effectiveness of prophylactic antibiotics in the prevention of postoperative complications after tension-free hernioplasty.

Authors:  Jian-Fang Li; Dan-Dan Lai; Xiao-Dong Zhang; Ai-Min Zhang; Kuan-Xue Sun; Heng-Gui Luo; Zhen Yu
Journal:  Can J Surg       Date:  2012-02       Impact factor: 2.089

2.  Prophylactic antibiotics in pediatric shunt surgery.

Authors:  N Biyani; G Grisaru-Soen; P Steinbok; S Sgouros; S Constantini
Journal:  Childs Nerv Syst       Date:  2006-05-18       Impact factor: 1.475

3.  Prophylactic antibiotics for mesh inguinal hernioplasty: a meta-analysis.

Authors:  Alvaro Sanabria; Luis Carlos Domínguez; Eduardo Valdivieso; Gabriel Gómez
Journal:  Ann Surg       Date:  2007-03       Impact factor: 12.969

4.  Predictive factors for the development of surgical site infection in adults undergoing initial open inguinal hernia repair.

Authors:  J Sereysky; A Parsikia; M E Stone; M Castaldi; J McNelis
Journal:  Hernia       Date:  2019-09-24       Impact factor: 4.739

5.  Prospective randomized evaluation of prophylactic antibiotic usage in patients undergoing tension free inguinal hernioplasty.

Authors:  I Othman
Journal:  Hernia       Date:  2011-01-23       Impact factor: 4.739

6.  Prophylactic Antibiotic Therapy in Contaminated Traumatic Wounds: Two Days versus Five Days Treatment.

Authors:  Hamed-Basir Ghafouri; Barzin Bagheri-Behzad; Mohammad-Reza Yasinzadeh; Ehsan Modirian; Dorsa Divsalar; Shervin Farahmand
Journal:  Bioimpacts       Date:  2012-03-17

7.  A prospective, double-blind, multicenter, randomized trial comparing ertapenem 3 vs >or=5 days in community-acquired intraabdominal infection.

Authors:  Antonio Basoli; Piero Chirletti; Ercole Cirino; Nicola G D'Ovidio; Giovanni Battista Doglietto; Domenico Giglio; Stefano M Giulini; Alberto Malizia; Mario Taffurelli; Jelena Petrovic; Maurizio Ecari
Journal:  J Gastrointest Surg       Date:  2007-09-11       Impact factor: 3.452

8.  A prospective, multi centre, randomized clinical study to compare the efficacy and safety of Ertapenem 3 days versus Ampicillin-Sulbactam 3 days in the treatment of localized community acquired intra-abdominal infection. (T.E.A. Study: Three days Ertapenem vs three days Ampicillin-sulbactam).

Authors:  Federico Coccolini; Fausto Catena; Luca Ansaloni; Giorgio Ercolani; Salomone Di Saverio; Filippo Gazzotti; Daniel Lazzareschi; Antonio D Pinna
Journal:  BMC Gastroenterol       Date:  2011-04-18       Impact factor: 3.067

9.  Prevention of early infective complications after laparoscopic splenectomy with the Garamycin sponge.

Authors:  Marcin Migaczewski; Anna Zub-Pokrowiecka; Piotr Budzyński; Maciej Matłok; Andrzej Budzyński
Journal:  Wideochir Inne Tech Maloinwazyjne       Date:  2012-03-27       Impact factor: 1.195

10.  T.E.A. Study: three-day ertapenem versus three-day Ampicillin-Sulbactam.

Authors:  Fausto Catena; Carlo Vallicelli; Luca Ansaloni; Massimo Sartelli; Salomone Di Saverio; Riccardo Schiavina; Eddi Pasqualini; Annalisa Amaduzzi; Federico Coccolini; Michele Cucchi; Daniel Lazzareschi; Gian Luca Baiocchi; Antonio D Pinna
Journal:  BMC Gastroenterol       Date:  2013-04-30       Impact factor: 3.067

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.